Castle Biosciences (CSTL) Amortization - Intangibles (2021 - 2026)

Castle Biosciences has disclosed Amortization - Intangibles across 6 years of filings, most recently posting $2.3 million for Q2 2026.

• In Q2 2026, Amortization - Intangibles rose 15.0% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $9.1 million (down 73.9% YoY), while the FY2025 annual figure was $34.8 million, up 213.69% from the prior year.
• Amortization - Intangibles came in at $2.3 million for Q2 2026 at Castle Biosciences, up from $2.2 million in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $28.3 million in Q1 2025 to a low of $1.6 million in Q1 2022.
• Average Amortization - Intangibles over 5 years is $3.6 million, with a median of $2.2 million recorded in 2024.
• Year-over-year, Amortization - Intangibles jumped 1160.57% in 2025 and tumbled 92.14% in 2026.
• Over 5 years, Amortization - Intangibles stood at $2.2 million in 2022, then rose by 3.23% to $2.3 million in 2023, then fell by 7.53% to $2.1 million in 2024, then climbed by 6.57% to $2.2 million in 2025, then climbed by 2.77% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Amortization - Intangibles figures were $2.3 million in Q2 2026, $2.2 million in Q1 2026, and $2.2 million in Q4 2025.